ArticlePloS one2017
Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- STAT3/p-STAT3 expression is correlated with clinicopathological characteristics and prognosis in non-small cell lung cancer.Histology and histopathology · 2025Article
- Multimodal Framework in Lung Cancer Management: Integrating Liquid Biopsy with Traditional Diagnostic Techniques.Cancer management and research · 2025Review
- The latest advances in liquid biopsy for lung cancer-a narrative review.Translational lung cancer research · 2024Review
- Impact of detecting plasma EGFR mutations with ultrasensitive liquid biopsy in outcomes of NSCLC patients treated with first- or second-generation EGFR-TKIs.Cancer biomarkers : section A of Disease markers · 2021Observational
- Cell-Free Circulating Tumour DNA Blood Testing to DetectOntario health technology assessment series · 2020Article
- Comparative Analysis of Two Methods for the Detection ofCancers · 2019Article
- EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer.Clinical and translational medicine · 2019Article
- Detection and application of circulating tumor cell and circulating tumor DNA in the non-small cell lung cancer.American journal of cancer research · 2018Review
- Different subtypes of EGFR exon19 mutation can affect prognosis of patients with non-small cell lung adenocarcinoma.PloS one · 2018Article
- Polymer nanofiber-based microchips for EGFR mutation analysis of circulating tumor cells in lung adenocarcinoma.International journal of nanomedicine · 2018Article
- Lung health in a changing world.The Medical journal of Australia · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveEpidermal growth factor receptor (EGFR) specific mutations have been known to improve survival of patients with non-small-cell lung carcinoma (NSCLC). However, whether there are any changes of EGFR mutations after targeted therapy and its clinical significance is unclear. This study was to identify the status of EGFR mutations after targeted therapy and predict the prognostic significance for NSCLC patients.
methodsA total of forty-five (45) NSCLC patients who received EGFR-TKI therapy were enrolled. We identified the changes of EGFR mutations in plasma ctDNA by Amplification Refractory Mutation System (ARMS) PCR technology.
resultsIn the 45 cases of NSCLC with EGFR mutations, the EGFR mutation status changed in 26 cases, in which, 12 cases (26.7%) from positive to negative, and 14 cases (31.1%) from T790M mutation negative to positive after TKI targeted therapy. The T790M occurance group had a shorter Progression -Free-Survival (PFS) than the groups of EGFR mutation undetected and EGFR mutation turned out to have no change after EGFR-TKI therapy (p < 0.05).
conclusionsAccording to this study, it's necessary to closely monitor EGFR mutations during follow-up to predict the prognosis of NSCLC patients who are to receive the TKI targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.